Jennifer Odren, DO
Nephrology · Saint Clair Shores, MINPI 1821384249
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 162 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Amgen at 24.5% of the total.
Across 162 payments — averaging $20.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$805
- Aurinia Pharma U.S., Inc.$290
- Novartis$282
- AstraZeneca$267
- Mallinckrodt Hospital Products Inc.$210
- Boehringer Ingelheim$198
- plus $1K from 17 others
Across 126 payments — averaging $4897.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$172K
- Akebia Therapeutics Inc$125K
- Vertex$125K
- AstraZeneca$112K
- Novo Nordisk AS$24K
- GSK$24K
- plus $34K from 2 others
What the payments were for
- Food & beverage$3,27199%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 40 | $805 |
| Aurinia Pharma U.S., Inc. | 14 | $290 |
| Novartis | 14 | $282 |
| AstraZeneca | 16 | $267 |
| Mallinckrodt Hospital Products Inc. | 9 | $210 |
| Boehringer Ingelheim | 9 | $198 |
| Otsuka America Pharmaceutical, Inc. | 5 | $175 |
| Bayer | 9 | $157 |
| Vifor Pharma, Inc. | 8 | $154 |
| Novo Nordisk | 6 | $122 |
| Ardelyx, Inc. | 5 | $106 |
| Calliditas Therapeutics US Inc. | 5 | $103 |
| Akebia Therapeutics Inc | 5 | $101 |
| Apellis Pharmaceuticals, Inc. | 2 | $69 |
| Fresenius USA Marketing, Inc. | 3 | $54 |
| Mallinckrodt Enterprises LLC | 2 | $42 |
| Daiichi Sankyo Inc. | 2 | $39 |
| ANI Pharmaceuticals, Inc. | 2 | $33 |
| Travere Therapeutics, Inc. | 2 | $20 |
| GSK | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $15 |
| Ascendis Pharma Endocrinology Inc | 1 | $14 |
How this compares
$3,291 in reported general payments places this provider in the 75th percentile of 325 nephrology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 14 | $15,034 |
| Sevelamer Carbonate | 11 | $11,542 |
| LokelmaSodium Zirconium Cyclosilicate | 17 | $8,182 |
| JardianceEmpagliflozin | 13 | $7,444 |
| Bumetanide | 90 | $5,036 |
| Calcium Acetate | 22 | $4,007 |
| Nifedipine ErNifedipine | 24 | $1,248 |
| Klor-Con M20Potassium Chloride | 17 | $1,204 |
| Potassium Chloride | 21 | $1,114 |
| Hydralazine Hcl | 21 | $524 |
| Metolazone | 19 | $496 |
| Tamsulosin Hcl | 28 | $493 |
| Allopurinol | 24 | $470 |
| Losartan Potassium | 32 | $405 |
| Calcitriol | 24 | $402 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $267 | $23,21631 claims |
| Boehringer IngelheimJardiance | $198 | $7,44413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 325 nephrology providers in Michigan.
Other nephrology in Saint Clair Shores
- Richard CrossSaint Clair Shores$96K
- Faten AyyoubSaint Clair Shores$5K
- Alexander YevzlinAnn Arbor$1.1M
- Muwaffaq SalamehBay City$164K
- Laura MarianiAnn Arbor$150K
- Crystal Gardner-MartinLivonia$140K
- Katherine KwonSaint Joseph$111K
- Anatole BesarabDetroit$102K
- Kausik UmanathDetroit$85K
- Joel TopfRoseville$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.